SI9010243B - Substituirani 1,3-oksatiolani z antivirusnimi lastnostmi - Google Patents
Substituirani 1,3-oksatiolani z antivirusnimi lastnostmi Download PDFInfo
- Publication number
- SI9010243B SI9010243B SI9010243A SI9010243A SI9010243B SI 9010243 B SI9010243 B SI 9010243B SI 9010243 A SI9010243 A SI 9010243A SI 9010243 A SI9010243 A SI 9010243A SI 9010243 B SI9010243 B SI 9010243B
- Authority
- SI
- Slovenia
- Prior art keywords
- oxathiolane
- compound
- formula
- group
- hydroxymethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Claims (12)
- -λ" PATENTNI ZAHTEVKI 1. Postopek za pridobivanje spojine s formulo (I)(I) kjer je Rj vodik; I^ je purinska ali pirimidinska baza ali njen analog ali derivat; Z je S, S=0 ali S02; in njenih farmacevtsko sprejemljivih derivatov, označen s tem, da obsega: (a) reakcijo spojine s formulo (VIII)(VIII) v kateri je R; vodik ali zaščitna skupina za hidroksilno skupino in je L zamenljiv atom ali skupina z bazno R^H skupino; (b) bazno interkonverzijo spojine s formulo (I) v drugo spojino s formulo (I); (c) reakcijo spojine s formulo (IX)
- 2. Postopek po zahtevku 1, označen s tem, da spojino s formulo (I) dobimo v obliki tis izomera.2 (IX) *s spojino s formulo (X) POCHO v kateri je P zaščitna skupina; ali (X) -Z' (d) konverzijo spojine s formulo (XII)(XII) v spojino s formulo (I), in če je potrebno ali želeno, izpostavitev spojine, dobljene v katerekoli stopnji od (a) do (d), eni ali dvem nadaljnjim reakcijam, ki obsegata: (i) odstranjevanje katerekoli zaščitne skupine; (ii) pretvorbo spojine s formulo (I) ali njene soli v njeno farmacevtsko sprejemljivo sol.
- 3. Postopek po zahtevku 1 ali 2, označen s tem, da Z predstavlja S.
- 4. Postopek po kateremkoli od zahtevkov 1 do 3, označen s tem, da je R2:'N -'b-oje R3 izbran iz skupine, ki jo sestavljajo vodik, trifluorometil ali nasičena ali nenasičena C16alkilna skupina; ·* R4 in R. sta neodvisno izbrana iz skupine, ki jo sestavljajo vodik, hidroksimetil. tri-tluorometil, substituiran ali nesubstituiran, nasičen ali nenasičen Ct 6alkil, brom. klor, fluor ali jod; R6 je izbran iz skupine, ki jo sestavljajo vodik, ciano, karboksi, etoksikarbonil. kar* bamoil ali tiokarbamoil; in sta X in Y sta neodvisno izbrana iz skupine, ki jo sestavljajo vodik, brom. klor. tluor, jod. amino ali hidroksilna skupina.
- 5. Postopek po kateremkoli od zahtevkov 1 do 3, označen s tem, daje R2: -Nikjer je R3 izbran iz skupine, ki jo sestavljajo vodik, trifluorometil ali nasičena ali nenasičena C16alkilna skupina in je R4 izbran iz skupine, ki jo sestavljajo vodik, hidroksimetil, trifluorometil, substituirana ali nesubstituirana, nasičena ali nenasičena C3 6alkilna skupina, brom, klor, fluor ali jod.
- 6. Postopek po kateremkoli od zahtevkov 1 do 5, označen s tem, da spojino s formulo (I) izberemo izmed: Cis-2-hidroksimetil-5-(citozin-Γ-il)-1.3-oksatiolana, trans-2-hidroksimetil-5 -f citozin-l’-il)-l,3-oksatiolana in njunih zmesi; Cis-2-benzoilksimetil-5-(citozin-l’-il)-l,3-oksatiolana, trans-2-benzoiloksimetil-5-(citozin-l’-il)-l,3-oksatioIana in njunih zmesi; Cis-2-hidroksimetil-5-(N4’-acetil-citozin-l’-il)-l,3-oksatiolana, trans-2-hidroksimetil-5-(N4’-acetil-citozin-l’-il)-l,3-oksatiolana in njunih zmesi; Cis-2-benzoiloksimetil-5-(N4’-acetil-citozin-l’-il)-l,3-oksatiolana, trans-2-benzoiloksimetil-5-(N4’-acetil-citozin-l’-il)-l,3-oksatiolana in njunih zmesi; in Qs-2-hidroksimetil-5-(citozin-l’-il-3-okso-l,3-oksatiolana); Cis-2-hidroksimetil-5-(N-dimetilamino-metilen citozin-l’-il)-l,3-oksatiolana; Bis-cis-2-sukciniloksimetil-5-(citozin-r-iD-l,3-oksatiolana; Cis-2-benzoiloksimetil-5-(6’-kloropurin-N-9’-il)-l,3-oksatiolana; trans-2-benzoiloksimetil-5-(6’-kloropurin-N-9’-il)-l,3-oksatiolana in njunih zmesi; Cis-2-hidroksimetil-5-(6’-hidroksipurin-N-9’-il)-l,3-oksatiolana; Cis-2-benzoiloksimetil-5-(uracil-N-r*il)-l,3-oksatiolana, trans-2-benzoiloksimetil-5- -5 " (uracil-N-l’-il)-l,3-oksatiolana in njunih zmesi; Cis-2-hidroksimetil-5-(uraciI-N-r-iQ-l,3-oksatiolana; Cis-2-benzoiloksimetil-5-(timin-N-r-il)-l,3-oksatiolana, trans-2-benzoiloksimetil-5-(timin-N-l’-il)-l,3-oksatiolana in njunih zmesi; Qs-2-hidroksimetil-5-(timin-N-l’-il)-l,3-oksatiolana; in njihovih farmacevtsko sprejemljivih derivatov v obliki racemnih zmesi ali posameznih enantiomerov.
- 7. Postopek po kateremkoli od zahtevkov 1 do 5, označen s tem, da je spojina s formulo (I) Cis-2-hidroksimetil-5-(citozin-r-il)-l,3-oksatiolan in njegovi farmacevtsko sprejemljivi derivati.
- 8. Postopek po kateremkoli od zahtevkov 1 do 7, označen s tem, da spojino s formulo (I) dobimo v obliki racemne zmesi.
- 9. Postopek po kateremkoli od zahtevkov 1 do 7, označen s tem, da spojino s formulo (I) dobimo v obliki posameznega enantiomera.
- 10. Postopek po kateremkoli od zahtevkov 1 do 9, označen s tem, da v stopnji (a) skupino L izberemo iz skupine, ki jo sestavljajo alkoksikarbonil, jod, brom, klor ali -OR, kjer je R substituirana ali nesubstituirana, nasičena ali nenasičena alkilna skupina ali je R substituirana ali nesubstituirana alifatska ali aromatska acilna skupina.
- 11. Postopek po kateremkoli od zahtevkov 1 do 10, označen s tem, da v stopnji (a) spojina s formulo (VIII) reagira s sililirano purinsko ali pirimidinsko bazo v ustreznem topilu v prisotnosti Lewisove kisline ali trimetilsililtriflata.
- 12. Postopek za pripravo farmacevtskega pripravka, označen s tem, da obsega mešanje spojine s formulo (I), kot je definirana v zahtevku 1, ali njenega farmacevtsko sprejemljivega derivata s farmacevtsko sprejemljivim nosilcem. Za BioChem Pharma Inc.:
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/308,101 US5047407A (en) | 1989-02-08 | 1989-02-08 | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
YU24390A YU48840B (sh) | 1989-02-08 | 1990-02-08 | Postupak za dobijanje substituisanih 1,3-oksatiolana sa antivirusnim osobinama |
CA002152269A CA2152269C (en) | 1989-02-08 | 1992-12-21 | Process for preparing substituted 1,3-oxathiolanes with antiviral properties |
Publications (2)
Publication Number | Publication Date |
---|---|
SI9010243A SI9010243A (en) | 1996-10-31 |
SI9010243B true SI9010243B (sl) | 1998-08-31 |
Family
ID=25678044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI9010243A SI9010243B (sl) | 1989-02-08 | 1990-02-08 | Substituirani 1,3-oksatiolani z antivirusnimi lastnostmi |
Country Status (35)
Country | Link |
---|---|
US (1) | US5047407A (sl) |
EP (2) | EP0382526B1 (sl) |
JP (4) | JP2644357B2 (sl) |
KR (1) | KR960007531B1 (sl) |
CN (1) | CN1033640C (sl) |
AP (1) | AP136A (sl) |
AT (2) | ATE138065T1 (sl) |
AU (1) | AU630913B2 (sl) |
CA (1) | CA2009637C (sl) |
CY (1) | CY2036A (sl) |
CZ (1) | CZ282720B6 (sl) |
DE (3) | DE69026971T2 (sl) |
DK (2) | DK0711771T3 (sl) |
ES (2) | ES2086371T3 (sl) |
FI (1) | FI98065C (sl) |
GR (1) | GR3019919T3 (sl) |
HK (2) | HK51997A (sl) |
HR (1) | HRP940040B1 (sl) |
HU (2) | HU208134B (sl) |
IE (1) | IE72184B1 (sl) |
IL (1) | IL93318A (sl) |
LU (1) | LU88809I2 (sl) |
MX (1) | MX19437A (sl) |
NL (1) | NL960025I2 (sl) |
NO (2) | NO179518C (sl) |
NZ (1) | NZ232421A (sl) |
OA (1) | OA09193A (sl) |
PL (1) | PL164785B1 (sl) |
PT (1) | PT93094B (sl) |
RU (1) | RU2092485C1 (sl) |
SG (2) | SG77215A1 (sl) |
SI (1) | SI9010243B (sl) |
SK (1) | SK279175B6 (sl) |
YU (1) | YU48840B (sl) |
ZA (1) | ZA90943B (sl) |
Families Citing this family (149)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5466806A (en) * | 1989-02-08 | 1995-11-14 | Biochem Pharma Inc. | Processes for preparing substituted 1,3-oxathiolanes with antiviral properties |
US6350753B1 (en) | 1988-04-11 | 2002-02-26 | Biochem Pharma Inc. | 2-Substituted-4-substituted-1,3-dioxolanes and use thereof |
US7119202B1 (en) | 1989-02-08 | 2006-10-10 | Glaxo Wellcome Inc. | Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties |
US5684164A (en) | 1988-04-11 | 1997-11-04 | Biochem Pharma Inc. | Processes for preparing substituted 1,3-oxathiolanes with antiviral properties |
US5270315A (en) * | 1988-04-11 | 1993-12-14 | Biochem Pharma Inc. | 4-(purinyl bases)-substituted-1,3-dioxlanes |
US6903224B2 (en) * | 1988-04-11 | 2005-06-07 | Biochem Pharma Inc. | Substituted 1,3-oxathiolanes |
US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
ES2196004T3 (es) * | 1989-02-08 | 2003-12-16 | Iaf Biochem Int | Procedimiento para preparar 1,3-oxatiolanos sustituidos con propiedades antivirales. |
UA45942A (uk) * | 1989-02-08 | 2002-05-15 | Біокем Фарма, Інк. | 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція |
US5276151A (en) * | 1990-02-01 | 1994-01-04 | Emory University | Method of synthesis of 1,3-dioxolane nucleosides |
US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US5700937A (en) * | 1990-02-01 | 1997-12-23 | Emory University | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
US5728575A (en) * | 1990-02-01 | 1998-03-17 | Emory University | Method of resolution of 1,3-oxathiolane nucleoside enantiomers |
US5914331A (en) * | 1990-02-01 | 1999-06-22 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
GB9009861D0 (en) * | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
US6369066B1 (en) | 1990-11-13 | 2002-04-09 | Biochem Pharma, Inc. | Substituted 1,3-oxathiolanes with antiviral properties |
US5587480A (en) * | 1990-11-13 | 1996-12-24 | Biochem Pharma, Inc. | Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties |
CA2095613C (en) * | 1990-11-13 | 2001-01-02 | Bernard Belleau | Substituted 1, 3-oxathiolanes and substituted 1, 3-dithiolanes with antiviral properties |
US6228860B1 (en) | 1990-11-13 | 2001-05-08 | Biochem Pharma Inc. | Substituted 1,3-oxathiolanes with antiviral properties |
US5248776A (en) * | 1990-12-05 | 1993-09-28 | University Of Georgia Research Foundation, Inc. | Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides |
AU9125991A (en) * | 1990-12-05 | 1992-07-08 | University Of Georgia Research Foundation, Inc., The | Enantiomerically pure beta -l-(-)-1,3-oxathiolane nucleosides |
US5179104A (en) * | 1990-12-05 | 1993-01-12 | University Of Georgia Research Foundation, Inc. | Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides |
US5925643A (en) | 1990-12-05 | 1999-07-20 | Emory University | Enantiomerically pure β-D-dioxolane-nucleosides |
US5444063A (en) * | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
IL100502A (en) * | 1991-01-03 | 1995-12-08 | Iaf Biochem Int | PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (- |
NZ241625A (en) * | 1991-02-22 | 1996-03-26 | Univ Emory | 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers |
US6812233B1 (en) * | 1991-03-06 | 2004-11-02 | Emory University | Therapeutic nucleosides |
PT100198B (pt) * | 1991-03-06 | 2000-03-31 | Univ Emory | Utilizacao de nucleosido oxatiolano para a preparacao de composicoes para fins terapeuticos |
GB9104740D0 (en) * | 1991-03-06 | 1991-04-17 | Wellcome Found | Antiviral nucleoside combination |
US5817667A (en) * | 1991-04-17 | 1998-10-06 | University Of Georgia Research Foudation | Compounds and methods for the treatment of cancer |
WO1992018517A1 (en) * | 1991-04-17 | 1992-10-29 | Yale University | Method of treating or preventing hepatitis b virus |
GB9109506D0 (en) * | 1991-05-02 | 1991-06-26 | Wellcome Found | Therapeutic nucleosides |
DK0513917T4 (da) * | 1991-05-16 | 2001-06-25 | Glaxo Group Ltd | Antivirale kombinationer indeholdende nukleosidanaloger |
GB9110874D0 (en) * | 1991-05-20 | 1991-07-10 | Iaf Biochem Int | Medicaments |
ZA923640B (en) * | 1991-05-21 | 1993-02-24 | Iaf Biochem Int | Processes for the diastereoselective synthesis of nucleosides |
GB9111902D0 (en) * | 1991-06-03 | 1991-07-24 | Glaxo Group Ltd | Chemical compounds |
GB9116601D0 (en) * | 1991-08-01 | 1991-09-18 | Iaf Biochem Int | 1,3-oxathiolane nucleoside analogues |
DE69120069T2 (de) * | 1991-09-04 | 1996-10-02 | Stichting Rega V Z W | Substituierte Nukleosidderivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen |
US20050192299A1 (en) * | 1992-04-16 | 2005-09-01 | Yung-Chi Cheng | Method of treating or preventing hepatitis B virus |
US6177435B1 (en) | 1992-05-13 | 2001-01-23 | Glaxo Wellcome Inc. | Therapeutic combinations |
WO1993023021A2 (en) * | 1992-05-13 | 1993-11-25 | The Wellcome Foundation Limited | Therapeutic combinations |
US6444656B1 (en) | 1992-12-23 | 2002-09-03 | Biochem Pharma, Inc. | Antiviral phosphonate nucleotides |
US6005107A (en) * | 1992-12-23 | 1999-12-21 | Biochem Pharma, Inc. | Antiviral compounds |
GB9226879D0 (en) * | 1992-12-23 | 1993-02-17 | Iaf Biochem Int | Anti-viral compounds |
GB9311709D0 (en) * | 1993-06-07 | 1993-07-21 | Iaf Biochem Int | Stereoselective synthesis of nucleoside analogues using bicycle intermediate |
WO1995007086A1 (en) | 1993-09-10 | 1995-03-16 | Emory University | Nucleosides with anti-hepatitis b virus activity |
US20020120130A1 (en) * | 1993-09-10 | 2002-08-29 | Gilles Gosselin | 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents |
US5587362A (en) * | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
IL113432A (en) * | 1994-04-23 | 2000-11-21 | Glaxo Group Ltd | Process for the diastereoselective synthesis of nucleoside analogues |
FR2720397B1 (fr) * | 1994-05-24 | 1996-08-23 | Laphal Laboratoires Sa | Nouveaux oxathiolanes, leur procédé de préparation et les compositions pharmaceutiques qui en renferment. |
IL115156A (en) * | 1994-09-06 | 2000-07-16 | Univ Georgia | Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines |
US5703058A (en) * | 1995-01-27 | 1997-12-30 | Emory University | Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent |
US6391859B1 (en) | 1995-01-27 | 2002-05-21 | Emory University | [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides |
US5808040A (en) * | 1995-01-30 | 1998-09-15 | Yale University | L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides |
MY115461A (en) | 1995-03-30 | 2003-06-30 | Wellcome Found | Synergistic combinations of zidovudine, 1592u89 and 3tc |
AU5527196A (en) * | 1995-04-04 | 1996-10-23 | Brigham And Women's Hospital | Inhibiting retroviral replication |
WO1996040164A1 (en) * | 1995-06-07 | 1996-12-19 | Emory University | Nucleosides with anti-hepatitis b virus activity |
GB9605293D0 (en) * | 1996-03-13 | 1996-05-15 | Glaxo Group Ltd | Medicaments |
FR2746396B1 (fr) * | 1996-03-20 | 1998-06-05 | Inst Nat Sante Rech Med | 1,3-thiazolidin-4-ones et 1,3-thiazolidines substituees, procede d'obtention de ces composes et leurs utilisations comme medicaments |
PL330747A1 (en) | 1996-06-25 | 1999-05-24 | Glaxo Group Ltd | Vx478, zidovudin, ftc and/or 3tc containing combinations for use in treating hiv infections |
US5753789A (en) * | 1996-07-26 | 1998-05-19 | Yale University | Oligonucleotides containing L-nucleosides |
US6113920A (en) * | 1996-10-31 | 2000-09-05 | Glaxo Wellcome Inc. | Pharmaceutical compositions |
US6022876A (en) * | 1996-11-15 | 2000-02-08 | Yale University | L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections |
US5792773A (en) * | 1996-11-15 | 1998-08-11 | Yale University | L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection |
US20040044016A1 (en) * | 1997-01-31 | 2004-03-04 | Mitsubishi Chemical Corporation | Antiviral agents |
EP0970078B1 (en) * | 1997-03-19 | 2004-05-19 | Emory University | Synthesis, anti-human immunodeficiency virus and anti-hepatitis b virus activities of 1,3-oxaselenolane nucleosides |
TW536403B (en) * | 1997-03-24 | 2003-06-11 | Glaxo Group Ltd | An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy |
IT1290447B1 (it) | 1997-03-28 | 1998-12-03 | Zambon Spa | Derivati 1,3-ossatiolanici ad attivita' antivirale |
EP0986375A2 (en) | 1997-04-07 | 2000-03-22 | Triangle Pharmaceuticals Inc. | Use of mkc-442 in combination with other antiviral agents |
EP1754710A3 (en) | 1998-02-25 | 2007-12-19 | Emory University | 2'-Fluoroncucleosides |
EA200700564A1 (ru) | 1998-02-25 | 2007-08-31 | Эмори Юниверсити | 2`-фторнуклеозиды |
CA2340214C (en) | 1998-08-12 | 2007-10-30 | Triangle Pharmaceuticals, Inc. | Method of manufacture of 1,3-oxathiolane nucleosides |
US6979561B1 (en) | 1998-10-09 | 2005-12-27 | Gilead Sciences, Inc. | Non-homogeneous systems for the resolution of enantiomeric mixtures |
AU1810600A (en) | 1998-11-02 | 2000-05-22 | Triangle Pharmaceuticals, Inc. | Combination therapy to treat hepatitis b virus |
JP2002528554A (ja) | 1998-11-05 | 2002-09-03 | サントル・ナシオナル・ドウ・ラ・ルシエルシユ・シアンテイフイク | B型肝炎ウイルス活性を持ったヌクレオシド |
EA004767B1 (ru) | 1998-12-23 | 2004-08-26 | Шайре Байокем Инк. | Аналоги нуклеозида (варианты) и их применение, комбинация и способ лечения вирусных инфекций, фармацевтическая композиция |
NZ529882A (en) * | 1999-03-29 | 2005-05-27 | Shire Biochem Inc | Methods of treating leukemia |
US6752929B1 (en) * | 1999-05-26 | 2004-06-22 | Johnson Matthey Pharmaceutical Materials, Inc. | Methods of separating FTC isomers and derivatives thereof |
DE60001821T2 (de) | 1999-05-26 | 2004-03-04 | Johnson Matthey Pharmaceutical Materials Inc., Devens | Verfahren zu trennung von ftc isomere und deren derivate |
US6653318B1 (en) * | 1999-07-21 | 2003-11-25 | Yale University | 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use |
US6432966B2 (en) * | 1999-10-29 | 2002-08-13 | Smithkline Beecham Corporation | Antiviral combinations |
EP1600452A3 (en) | 1999-11-12 | 2008-09-10 | Pharmasset, Inc. | Synthesis of 2'-deoxy-L-nucleosides |
CN1919859A (zh) * | 1999-11-12 | 2007-02-28 | 法玛赛特有限公司 | 2'-脱氧-l-核苷的合成 |
US6436948B1 (en) | 2000-03-03 | 2002-08-20 | University Of Georgia Research Foundation Inc. | Method for the treatment of psoriasis and genital warts |
GB0016845D0 (en) * | 2000-07-07 | 2000-08-30 | Leuven K U Res & Dev | Pharmaceutical composition for treatment of HIV infection |
WO2002051852A1 (fr) * | 2000-12-27 | 2002-07-04 | Mitsui Chemicals, Inc. | Procede de production d'un derive de saccharide non naturel |
CA2788498C (en) | 2001-03-01 | 2016-02-16 | Gilead Sciences, Inc. | Polymorphic and other crystalline forms of cis-ftc |
US6600044B2 (en) | 2001-06-18 | 2003-07-29 | Brantford Chemicals Inc. | Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers |
JP2003039582A (ja) * | 2001-07-19 | 2003-02-13 | Three M Innovative Properties Co | 湿潤防滑性シート及び湿潤防滑構造体 |
MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
US6855346B2 (en) * | 2001-10-05 | 2005-02-15 | Tzu-Sheng Wu | Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same |
ES2258668T3 (es) * | 2001-10-26 | 2006-09-01 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Hidroxipirimidina carboxamidas n-sustituidas inhibidoras de hiv integrasa. |
CN1620295A (zh) * | 2001-12-14 | 2005-05-25 | 法玛塞特有限公司 | 制备用于合成抗病毒核苷的中间体 |
JP4625637B2 (ja) | 2002-02-22 | 2011-02-02 | シャイア エルエルシー | 活性物質送達系及び活性物質を保護し投与する方法 |
ATE496054T1 (de) | 2002-08-06 | 2011-02-15 | Pharmasset Inc | Verfahren zur herstellung von 1,3-dioxolan- nucleosiden |
DE10238722A1 (de) * | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
DE10238723A1 (de) * | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
WO2004043433A2 (en) * | 2002-11-08 | 2004-05-27 | Glaxo Group Limited | Pharmaceutical antiviral compositions |
EP1569659A4 (en) * | 2002-12-09 | 2009-03-25 | Univ Georgia Res Found | DIOXOLAN THYMIN AND COMBINATIONS AGAINST 3TC / AZT RESISTANT HIV STRAINS |
CN105596356A (zh) | 2003-01-14 | 2016-05-25 | 吉里德科学公司 | 用于联合抗病毒治疗的组合物和方法 |
DE10320785A1 (de) * | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Arylmethyl-substituierte Pyrazolopyrimidine |
US8044060B2 (en) * | 2003-05-09 | 2011-10-25 | Boehringer Ingelheim International Gmbh | 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory |
DE102004001873A1 (de) * | 2004-01-14 | 2005-09-29 | Bayer Healthcare Ag | Cyanopyrimidinone |
PL216369B1 (pl) | 2004-07-27 | 2014-03-31 | Gilead Sciences | Pochodne fosfonianowe, kompozycje farmaceutyczne zawierające te pochodne oraz zastosowanie tych pochodnych do wytwarzania leku do hamowania wirusa HIV |
JP2006214695A (ja) * | 2005-02-07 | 2006-08-17 | Sanken Setsubi Kogyo Co Ltd | 空調システム |
TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
US20070059360A1 (en) * | 2005-07-29 | 2007-03-15 | Ashish Jaiswal | Water-dispersible anti-retroviral pharmaceutical compositions |
CN1328240C (zh) * | 2005-08-31 | 2007-07-25 | 四川大学 | 苯甲酰氧基乙醛的制备方法 |
CA2620853A1 (en) * | 2005-08-31 | 2007-03-08 | Cipla Limited | Pharmaceutical combinations containing lamivudine, stavudine and nevirapine |
NZ567272A (en) | 2005-09-26 | 2012-02-24 | Pharmasset Inc | Modified 4'-nucleosides as antiviral agents |
WO2007068934A2 (en) * | 2005-12-14 | 2007-06-21 | Cipla Limited | Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit |
US8895531B2 (en) * | 2006-03-23 | 2014-11-25 | Rfs Pharma Llc | 2′-fluoronucleoside phosphonates as antiviral agents |
WO2007119248A1 (en) * | 2006-04-18 | 2007-10-25 | Lupin Limited | A novel crystalline form of lamivudine |
US20110257396A1 (en) * | 2006-10-30 | 2011-10-20 | Lupin Limited | Process for the manufacture of cis(-)-lamivudine |
KR100840495B1 (ko) | 2007-04-13 | 2008-06-23 | 한미약품 주식회사 | 라미부딘을 입체선택적으로 제조하는 방법 |
US8236797B2 (en) | 2007-06-18 | 2012-08-07 | Sunshine Lake Pharma Co., Ltd. | Bromo-phenyl substituted thiazolyl dihydropyrimidines |
US20100190982A1 (en) * | 2007-09-17 | 2010-07-29 | Janardhana Rao Vascuri | Process for the preparation of lamivudine form i |
CN101918416A (zh) * | 2007-11-29 | 2010-12-15 | 兰贝克赛实验室有限公司 | 制备取代的1,3-氧硫杂环戊烷,尤其是拉米夫定的方法和中间体 |
EP2225232B1 (en) * | 2007-11-29 | 2012-09-26 | Ranbaxy Laboratories Limited | Process for the preparation of substituted 1,3-oxathiolanes |
PE20091211A1 (es) * | 2007-11-30 | 2009-09-14 | Boehringer Ingelheim Int | Derivados de pirazolopirimidina como moduladores de pde9a |
UA105362C2 (en) * | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
TW201010692A (en) | 2008-06-19 | 2010-03-16 | Public Univ Corp Nagoya City Univ | Pharmaceutical composition for treatment or prevention of hbv infection |
MX2011002340A (es) | 2008-09-08 | 2011-04-04 | Boehringer Ingelheim Int | Pirazolopirimidinas y su uso para el tratamiento de trastornos del snc. |
UY32306A (es) | 2008-12-09 | 2010-07-30 | Gilead Sciences Inc | Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos |
US20110282046A1 (en) * | 2009-01-19 | 2011-11-17 | Rama Shankar | Process for preparation of cis-nucleoside derivative |
AP2011005819A0 (en) | 2009-03-31 | 2011-08-31 | Boehringer Ingelheim Int | 1-heterocyclyl-1, 5-dihydropyrazolo[3,4-D] pyrimidin -4-one derivatives and their use as PDE9A modulators. |
KR101474570B1 (ko) | 2009-04-13 | 2014-12-19 | 주식회사 대희화학 | 라미부딘의 신규한 중간체 및 이의 제조방법 |
TW201118099A (en) * | 2009-08-12 | 2011-06-01 | Boehringer Ingelheim Int | New compounds for the treatment of CNS disorders |
EP2488516B1 (en) | 2009-10-14 | 2015-04-01 | Mylan Laboratories Limited | Process for the preparation of lamivudine and novel salts in the manufacture thereof |
CA3003988C (en) | 2010-01-27 | 2020-01-07 | Viiv Healthcare Company | Combinations for use in the inhibition of hiv-1 |
WO2011095987A1 (en) | 2010-02-03 | 2011-08-11 | Matrix Laboratories Ltd. | Novel process for the preparation of cis-nucleoside derivative |
US20110223131A1 (en) | 2010-02-24 | 2011-09-15 | Gilead Sciences, Inc. | Antiviral compounds |
CN102234269B (zh) * | 2010-04-29 | 2015-09-16 | 重庆医药工业研究院有限责任公司 | 拉米夫定的工业化制备方法 |
WO2011141805A2 (en) | 2010-05-14 | 2011-11-17 | Lupin Limited | An improved process for the manufacture of lamivudine |
US20130115237A1 (en) | 2010-06-09 | 2013-05-09 | Vaccine Technologies, Incorporated | Therapeutic immunization in hiv infected subjects to augment antiretroviral treatment |
JP5756176B2 (ja) | 2010-08-12 | 2015-07-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 6−シクロアルキル−1,5−ジヒドロ−ピラゾロ(3,4−d)ピリミジ−4−オン誘導体及びpde9a阻害剤としてのその使用 |
US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
EP2739620A1 (en) | 2011-08-05 | 2014-06-11 | Lupin Limited | A stereoselective process for preparation of 1,3-oxathiolane nucleosides |
WO2013168066A1 (en) | 2012-05-05 | 2013-11-14 | Lupin Limited | An improved process for the manufacture of lamivudine form i. |
CN103694231A (zh) * | 2013-11-28 | 2014-04-02 | 安徽一帆香料有限公司 | 一种拉米夫定中间体hdms的合成制备方法 |
WO2016001907A1 (en) | 2014-07-02 | 2016-01-07 | Prendergast Patrick T | Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents. |
TWI806081B (zh) | 2014-07-11 | 2023-06-21 | 美商基利科學股份有限公司 | 用於治療HIV之toll樣受體調節劑 |
WO2016033164A1 (en) | 2014-08-26 | 2016-03-03 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
EP3349757A1 (en) | 2015-09-15 | 2018-07-25 | Gilead Sciences, Inc. | Modulators of toll-like recptors for the treatment of hiv |
MX2018006773A (es) | 2015-12-02 | 2018-08-01 | Merck Sharp & Dohme | Composiciones farmaceuticas que contienen doravirina, tenofovir disoproxil fumarato y lamivudina. |
WO2018178722A1 (en) * | 2017-03-31 | 2018-10-04 | The University Of Liverpool | Prodrug compositions |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4000137A (en) * | 1975-06-10 | 1976-12-28 | American Home Products Corporation | Antitumor derivatives of periodate-oxidized nucleosides |
JPS5259171A (en) * | 1975-11-10 | 1977-05-16 | Asahi Chem Ind Co Ltd | Preparation of uracil derivatives |
JPS6045196B2 (ja) * | 1976-08-09 | 1985-10-08 | 株式会社興人 | 1−(2−テトラヒドロフリル)ウラシル類の製造方法 |
JPS5668674A (en) * | 1979-11-08 | 1981-06-09 | Shionogi & Co Ltd | 5-fluorouracil derivative |
JPS56167685A (en) * | 1980-05-28 | 1981-12-23 | Taiho Yakuhin Kogyo Kk | 1- 2-tetrahydrothiophene-1,1-dioxide -5-fluorouracil and its preparation |
JPS56169689A (en) * | 1980-06-02 | 1981-12-26 | Taiho Yakuhin Kogyo Kk | 3-substituted-5-fluorouracil derivative and its preparation |
JPS5738774A (en) * | 1980-08-19 | 1982-03-03 | Chugai Pharmaceut Co Ltd | Uracil derivative and its preparation |
SU1035023A1 (ru) * | 1982-03-23 | 1983-08-15 | Ордена Трудового Красного Знамени Институт Органической И Физической Химии Им.А.Е.Арбузова | Способ получени 3-(тииранил-2-метил)-6-метилурацилов |
DE3324769A1 (de) * | 1983-07-08 | 1985-01-17 | Bayer Ag, 5090 Leverkusen | 5-aminomethyl-1,3-oxathiolane |
NZ216172A (en) * | 1985-05-15 | 1989-08-29 | Wellcome Found | Nucleosides and pharmaceutical compositions |
CA1294960C (en) * | 1986-10-24 | 1992-01-28 | Thomas C. Malone | 7-deazaguanines as immunomodulators |
DE3712735A1 (de) * | 1987-04-15 | 1988-11-10 | Boehringer Mannheim Gmbh | Neue pyrazolo(3,4-d)pyrimidine, verfahren zu ihrer herstellung und verwendung als arzneimittel |
ES2075040T3 (es) * | 1988-02-16 | 1995-10-01 | Lilly Co Eli | 2',3'-dideoxi-2',2'-difluoronucleosidos. |
US5047407A (en) * | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
NZ228645A (en) * | 1988-04-11 | 1991-09-25 | Iaf Biochem Int | 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections |
US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
-
1989
- 1989-02-08 US US07/308,101 patent/US5047407A/en not_active Expired - Lifetime
-
1990
- 1990-02-07 RU SU904743202A patent/RU2092485C1/ru active
- 1990-02-07 HU HU90708A patent/HU208134B/hu unknown
- 1990-02-08 SG SG1999000115A patent/SG77215A1/en unknown
- 1990-02-08 IL IL9331890A patent/IL93318A/en not_active IP Right Cessation
- 1990-02-08 ZA ZA90943A patent/ZA90943B/xx unknown
- 1990-02-08 NZ NZ232421A patent/NZ232421A/xx unknown
- 1990-02-08 DK DK95120531T patent/DK0711771T3/da active
- 1990-02-08 PT PT93094A patent/PT93094B/pt active IP Right Grant
- 1990-02-08 MX MX1943790A patent/MX19437A/es unknown
- 1990-02-08 OA OA59735A patent/OA09193A/xx unknown
- 1990-02-08 DE DE69026971T patent/DE69026971T2/de not_active Expired - Lifetime
- 1990-02-08 EP EP90301335A patent/EP0382526B1/en not_active Expired - Lifetime
- 1990-02-08 AT AT90301335T patent/ATE138065T1/de active
- 1990-02-08 EP EP95120531A patent/EP0711771B1/en not_active Expired - Lifetime
- 1990-02-08 JP JP2031324A patent/JP2644357B2/ja not_active Expired - Lifetime
- 1990-02-08 LU LU88809C patent/LU88809I2/fr unknown
- 1990-02-08 ES ES90301335T patent/ES2086371T3/es not_active Expired - Lifetime
- 1990-02-08 FI FI900631A patent/FI98065C/fi active IP Right Grant
- 1990-02-08 CA CA002009637A patent/CA2009637C/en not_active Expired - Lifetime
- 1990-02-08 YU YU24390A patent/YU48840B/sh unknown
- 1990-02-08 KR KR1019900001493A patent/KR960007531B1/ko not_active IP Right Cessation
- 1990-02-08 IE IE45290A patent/IE72184B1/en not_active IP Right Cessation
- 1990-02-08 DE DE1996175032 patent/DE19675032I2/de active Active
- 1990-02-08 NO NO900619A patent/NO179518C/no not_active IP Right Cessation
- 1990-02-08 CN CN90100612A patent/CN1033640C/zh not_active Expired - Lifetime
- 1990-02-08 ES ES95120531T patent/ES2206476T3/es not_active Expired - Lifetime
- 1990-02-08 DK DK90301335.7T patent/DK0382526T3/da active
- 1990-02-08 SI SI9010243A patent/SI9010243B/sl unknown
- 1990-02-08 AT AT95120531T patent/ATE254125T1/de not_active IP Right Cessation
- 1990-02-08 PL PL90283692A patent/PL164785B1/pl unknown
- 1990-02-08 AU AU49201/90A patent/AU630913B2/en not_active Expired
- 1990-02-08 SG SG1996001044A patent/SG48737A1/en unknown
- 1990-02-08 AP APAP/P/1990/000163A patent/AP136A/en active
- 1990-02-08 DE DE69034119T patent/DE69034119T2/de not_active Expired - Lifetime
-
1991
- 1991-12-27 CZ CS914109A patent/CZ282720B6/cs not_active IP Right Cessation
- 1991-12-27 SK SK4109-91A patent/SK279175B6/sk unknown
-
1994
- 1994-01-24 HR HR940040A patent/HRP940040B1/xx not_active IP Right Cessation
- 1994-12-15 HU HU94P/P00058P patent/HU210537A9/hu unknown
-
1995
- 1995-08-16 JP JP07208936A patent/JP3105154B2/ja not_active Expired - Fee Related
-
1996
- 1996-05-16 GR GR960400767T patent/GR3019919T3/el unknown
- 1996-10-10 NL NL960025C patent/NL960025I2/nl unknown
-
1997
- 1997-04-24 HK HK51997A patent/HK51997A/xx not_active IP Right Cessation
-
1998
- 1998-02-20 CY CY203698A patent/CY2036A/xx unknown
- 1998-08-12 HK HK98109873A patent/HK1009270A1/xx not_active IP Right Cessation
-
1999
- 1999-12-27 JP JP11370063A patent/JP2000143662A/ja active Pending
-
2001
- 2001-01-25 NO NO2001002C patent/NO2001002I1/no unknown
- 2001-03-05 JP JP2001059730A patent/JP2001226373A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI9010243B (sl) | Substituirani 1,3-oksatiolani z antivirusnimi lastnostmi | |
EP0269574A3 (en) | Novel adenosine derivatives and pharmaceutical compositions containing them as an active ingredient | |
ATE22889T1 (de) | 8-chlor-1,5-benzothiazepinderivate, verfahren zur herstellung und pharmazeutische zusammensetzungen. | |
WO1994003467B1 (en) | Antiretroviral enantiomeric nucleotide analogs | |
HUT54981A (en) | Process for producing acryloyl-substituted pyrrole derivatives and pharmaceutical compositions comprising same | |
KR940014397A (ko) | 비사이클릭 아민 유도체 | |
DE60002755D1 (de) | Benzothiadiazinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen | |
DE69007905T2 (de) | 1-Oxa-2-oxo-8-azaspiro[4,5]decan-Derivate, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen daraus. | |
ATE32221T1 (de) | 3 n-substituierte 3,4-dihydropyrimidinderivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen. | |
ATE40997T1 (de) | 1,5-benzothiazepin-derivate, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen sowie ihre verwendung. | |
AU2008203443B2 (en) | Stereoselective method for the preparation of nucleoside analogues | |
KR920016456A (ko) | 5-(치환 아미노) -1,2,4-트리아졸로 [1,5-a]피리미딘 유도체 | |
ATE23995T1 (de) | Pyridin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
ATE41659T1 (de) | Benzothiazepinderivate, verfahren zur herstellung und pharmazeutische zusammensetzungen. | |
KR927003589A (ko) | p-치환된 페닐 4-옥시부탄 아민 유도체, 그것의 제조방법 및 그것을 함유하는 약제조성물 | |
DE69106323T2 (de) | Imidazol-Derivate, Verfahren zu deren Herstellung und diese enthaltende Zusammenstellungen. | |
DE60011787D1 (de) | Carbocyclische nukleoside und verfahren zu deren herstellung | |
ATE109154T1 (de) | 2'-methylidenpyrimidin-nukleoside, ihre verwendung und verfahren zu ihrer herstellung. | |
KR910004632A (ko) | 신규한 1-옥사-2-옥소-8-아자스피로[4,5]데칸 유도체와 그들을 포함하는 약제학적 조성물 및 그 제조방법 | |
DE3770117D1 (de) | Neue 1-/ 3-(2-dialkylaminoaethoxy)-2-thienyl/-3-phenyl-1-propanone und ihre saeureadditionssalze und verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen. | |
ATE93524T1 (de) | Mitomycinanaloge, verfahren zu ihrer herstellung und pharmazeutische zubereitungen. | |
ATE23150T1 (de) | Aminoethoxybenzylalkohol-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
EP0246529A3 (en) | Long acting pyrrolo (2,3-g) isoquinolin-4-one derivatives | |
AU647704B2 (en) | 1,2,3,6-tetrahydropyridine derivatives useful for improving cerebal blood circulation | |
ATE22683T1 (de) | Substituiertes heterocyclylphenylsulphonyl und phosphonylamidine, verfahren zu deren herstellung und deren pharmazeutische anwendung. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
IF | Valid on the event date | ||
SP73 | Change of data on owner |
Owner name: SHIRE BIOCHEM INC.; CA Effective date: 20060111 |
|
SP73 | Change of data on owner |
Owner name: SHIRE CANADA INC.; CA Effective date: 20090430 |